Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[ESMO ECCO 2015: The highlights of immunotherapy and targeted therapies].
Bonnet C, Beinse G, Cabel L, Cochereau D, Lavaud P, Rochefort P, Tabouret E, Turpin A, Verlingue L, Vicier C, Massard C. Bonnet C, et al. Among authors: cabel l. Bull Cancer. 2016 Jun;103(6):594-603. doi: 10.1016/j.bulcan.2016.04.001. Epub 2016 May 24. Bull Cancer. 2016. PMID: 27229364 French.
Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.
Cabel L, Fuerea A, Lacroix L, Baldini C, Martin P, Hollebecque A, Postel-Vinay S, Varga A, Balheda R, Gazzah A, Michot JM, Marabelle A, Rouleau E, Solary E, De Baere T, Angevin E, Armand JP, Michiels S, Scoazec JY, Ammari S, André F, Soria JC, Massard C, Verlingue L. Cabel L, et al. Oncotarget. 2018 Jan 12;9(11):9741-9750. doi: 10.18632/oncotarget.24188. eCollection 2018 Feb 9. Oncotarget. 2018. PMID: 29515767 Free PMC article.
Outcomes of patients with HER2-negative metastatic breast cancer after platinum- and non-platinum-based first-line chemotherapy among patients with and without pathogenic germline BRCA1/2 mutations.
Jacot W, Lusque A, Vicier C, Mailliez A, de La Motte Rouge T, Cabel L, Levy C, Patsouris A, Desmoulins I, Uwer L, Thery JC, Robain M, Caron O, Tredan O, Filleron T, Frenel JS, Delaloge S. Jacot W, et al. Among authors: cabel l. Br J Cancer. 2022 Nov;127(11):1963-1973. doi: 10.1038/s41416-022-02003-1. Epub 2022 Oct 7. Br J Cancer. 2022. PMID: 36207609 Free PMC article. Clinical Trial.
Circulating tumor cell count and thrombosis in metastatic breast cancer.
Beinse G, Berger F, Cottu P, Dujaric ME, Kriegel I, Guilhaume MN, Diéras V, Cabel L, Pierga JY, Bidard FC. Beinse G, et al. Among authors: cabel l. J Thromb Haemost. 2017 Oct;15(10):1981-1988. doi: 10.1111/jth.13792. Epub 2017 Sep 1. J Thromb Haemost. 2017. PMID: 28779538 Free article.
[Squamous cell anal carcinoma. What's next ?].
Kim S, Spehner L, Cabel L, Bidard FC, Borg C. Kim S, et al. Among authors: cabel l. Bull Cancer. 2021 Jan;108(1):80-89. doi: 10.1016/j.bulcan.2020.12.001. Epub 2021 Jan 8. Bull Cancer. 2021. PMID: 33423780 Review. French.
Tumour growth rate improves tumour assessment and first-line systemic treatment decision-making for immunotherapy in patients with liver metastatic uveal melanoma.
Ramtohul T, Cohen A, Rodrigues M, Piperno-Neumann S, Cabel L, Cassoux N, Lumbroso-Le Rouic L, Malaise D, Gardrat S, Pierron G, Mariani P, Servois V. Ramtohul T, et al. Among authors: cabel l. Br J Cancer. 2022 Jul;127(2):258-267. doi: 10.1038/s41416-022-01793-8. Epub 2022 Mar 26. Br J Cancer. 2022. PMID: 35347325 Free PMC article.
76 results